Literature DB >> 27490690

Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.

Huaijun Wang1, Amelie M Lutz1, Dimitre Hristov1, Lu Tian1, Jürgen K Willmann1.   

Abstract

Purpose To perform an intra-animal comparison between (a) three-dimensional (3D) molecularly targeted ultrasonography (US) by using clinical-grade vascular endothelial growth factor receptor 2 (VEGFR2)-targeted microbubbles and (b) 3D dynamic contrast material-enhanced (DCE) US by using nontargeted microbubbles for assessment of antiangiogenic treatment effects in a murine model of human colon cancer. Materials and Methods Twenty-three mice with human colon cancer xenografts were randomized to receive either single-dose antiangiogenic treatment (bevacizumab, n = 14) or control treatment (saline, n = 9). At baseline and 24 hours after treatment, animals were imaged with a clinical US system equipped with a clinical matrix array transducer by using the following techniques: (a) molecularly targeted US with VEGFR2-targeted microbubbles, (b) bolus DCE US with nontargeted microbubbles, and (c) destruction-replenishment DCE US with nontargeted microbubbles. VEGFR2-targeted US signal, peak enhancement, area under the time-intensity curve, time to peak, relative blood volume (rBV), relative blood flow, and blood flow velocity were quantified. VEGFR2 expression and percentage area of blood vessels were assessed ex vivo with quantitative immunofluorescence and correlated with corresponding in vivo US parameters. Statistical analysis was performed with Wilcoxon signed rank tests and rank sum tests, as well as Pearson correlation analysis. Results Molecularly targeted US signal with VEGFR2-targeted microbubbles, peak enhancement, and rBV significantly decreased (P ≤ .03) after a single antiangiogenic treatment compared with those in the control group; similarly, ex vivo VEGFR2 expression (P = .03) and percentage area of blood vessels (P = .03) significantly decreased after antiangiogenic treatment. Three-dimensional molecularly targeted US signal correlated well with VEGFR2 expression (r = 0.86, P = .001), and rBV (r = 0.71, P = .01) and relative blood flow (r = 0.78, P = .005) correlated well with percentage area of blood vessels, while other US perfusion parameters did not. Conclusion Three-dimensional molecularly targeted US and destruction-replenishment 3D DCE US provide complementary molecular and functional in vivo imaging information on antiangiogenic treatment effects in human colon cancer xenografts compared with ex vivo reference standards. © RSNA, 2016 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27490690      PMCID: PMC5283869          DOI: 10.1148/radiol.2016160032

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  42 in total

1.  Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion.

Authors:  K Wei; A R Jayaweera; S Firoozan; A Linka; D M Skyba; S Kaul
Journal:  Circulation       Date:  1998-02-10       Impact factor: 29.690

Review 2.  Ultrasound molecular imaging: Moving toward clinical translation.

Authors:  Lotfi Abou-Elkacem; Sunitha V Bachawal; Jürgen K Willmann
Journal:  Eur J Radiol       Date:  2015-03-21       Impact factor: 3.528

3.  Quantitative mapping of tumor vascularity using volumetric contrast-enhanced ultrasound.

Authors:  Kenneth Hoyt; Anna Sorace; Reshu Saini
Journal:  Invest Radiol       Date:  2012-03       Impact factor: 6.016

Review 4.  Ultrasound in Radiology: From Anatomic, Functional, Molecular Imaging to Drug Delivery and Image-Guided Therapy.

Authors:  Alexander L Klibanov; John A Hossack
Journal:  Invest Radiol       Date:  2015-09       Impact factor: 6.016

5.  Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.

Authors:  Huaijun Wang; Osamu F Kaneko; Lu Tian; Dimitre Hristov; Jürgen K Willmann
Journal:  Invest Radiol       Date:  2015-05       Impact factor: 6.016

6.  Quantitative assessment of tumor blood flow changes in a murine breast cancer model after adriamycin chemotherapy using contrast-enhanced destruction-replenishment sonography.

Authors:  Jian-Wei Wang; Wei Zheng; Yao Chen; Long-Hui Cao; Rong-Zhen Luo; An-Hua Li; Jian-Hua Zhou
Journal:  J Ultrasound Med       Date:  2013-04       Impact factor: 2.153

7.  Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound.

Authors:  Moritz Palmowski; Wiltrud Lederle; Jessica Gaetjens; Michaela Socher; Peter Hauff; Jessica Bzyl; Wolfhard Semmler; Rolf W Günther; Fabian Kiessling
Journal:  Eur J Radiol       Date:  2009-11-27       Impact factor: 3.528

8.  Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.

Authors:  Maria Assunta Zocco; Matteo Garcovich; Andrea Lupascu; Enrico Di Stasio; Davide Roccarina; Brigida Elenora Annicchiarico; Laura Riccardi; Maria Elena Ainora; Francesca Ponziani; Gianluigi Caracciolo; Gian Lodovico Rapaccini; Raffaele Landolfi; Massimo Siciliano; Maurizio Pompili; Antonio Gasbarrini
Journal:  J Hepatol       Date:  2013-06-25       Impact factor: 25.083

Review 9.  Functional and molecular ultrasound imaging: concepts and contrast agents.

Authors:  F Kiessling; J Huppert; M Palmowski
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

10.  Optimization of Ultrasound-mediated Anti-angiogenic Cancer Gene Therapy.

Authors:  Hiroko Fujii; Pratiek Matkar; Christine Liao; Dmitriy Rudenko; Paul Jh Lee; Michael A Kuliszewski; Gerald J Prud'homme; Howard Leong-Poi
Journal:  Mol Ther Nucleic Acids       Date:  2013-05-21       Impact factor: 10.183

View more
  12 in total

1.  Assessment of angiogenesis in rabbit orthotropic liver tumors using three-dimensional dynamic contrast-enhanced ultrasound compared with two-dimensional DCE-US.

Authors:  Qiao Zheng; Jian-Chao Zhang; Zhu Wang; Si-Min Ruan; Wei Li; Fu-Shun Pan; Li-Da Chen; Yu-Chen Zhang; Wen-Xin Wu; Xiao-Yan Xie; Ming-De Lu; Quan-Yuan Shan; Wei Wang
Journal:  Jpn J Radiol       Date:  2019-08-10       Impact factor: 2.374

2.  Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results.

Authors:  Jürgen K Willmann; Lorenzo Bonomo; Antonia Carla Testa; Pierluigi Rinaldi; Guido Rindi; Keerthi S Valluru; Gianluigi Petrone; Maurizio Martini; Amelie M Lutz; Sanjiv S Gambhir
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

Review 3.  Emerging contrast-enhanced ultrasound applications in children.

Authors:  Ryne A Didier; David M Biko; Misun Hwang; Sunil Unnikrishnan; Magdalena M Woźniak; Gibran T Yusuf; Anush Sridharan
Journal:  Pediatr Radiol       Date:  2021-04-01

4.  Bursting Microbubbles: How Nanobubble Contrast Agents Can Enable the Future of Medical Ultrasound Molecular Imaging and Image-Guided Therapy.

Authors:  Agata A Exner; Michael C Kolios
Journal:  Curr Opin Colloid Interface Sci       Date:  2021-05-02       Impact factor: 8.209

5.  Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging.

Authors:  Jianhua Zhou; Huiping Zhang; Huaijun Wang; Amelie M Lutz; Ahmed El Kaffas; Lu Tian; Dimitre Hristov; Jürgen K Willmann
Journal:  Angiogenesis       Date:  2017-07-18       Impact factor: 9.596

6.  A new preclinical ultrasound platform for widefield 3D imaging of rodents.

Authors:  Tomasz J Czernuszewicz; Virginie Papadopoulou; Juan D Rojas; Rajalekha M Rajamahendiran; Jonathan Perdomo; James Butler; Max Harlacher; Graeme O'Connell; Dženan Zukić; Stephen R Aylward; Paul A Dayton; Ryan C Gessner
Journal:  Rev Sci Instrum       Date:  2018-07       Impact factor: 1.523

7.  Ultrasound Measurement of Vascular Density to Evaluate Response to Anti-Angiogenic Therapy in Renal Cell Carcinoma.

Authors:  Juan D Rojas; Virginie Papadopoulou; Tomasz J Czernuszewicz; Rajalekha M Rajamahendiran; Anna Chytil; Yun-Chen Chiang; Diana C Chong; Victoria L Bautch; W Kimryn Rathmell; Stephen Aylward; Ryan C Gessner; Paul A Dayton
Journal:  IEEE Trans Biomed Eng       Date:  2018-07-27       Impact factor: 4.538

8.  68Ga-TRAP-(RGD)3 Hybrid Imaging for the In Vivo Monitoring of αvß3-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer.

Authors:  Philipp M Kazmierczak; Andrei Todica; Franz-Josef Gildehaus; Heidrun Hirner-Eppeneder; Matthias Brendel; Ralf S Eschbach; Magdalena Hellmann; Konstantin Nikolaou; Maximilian F Reiser; Hans-Jürgen Wester; Saskia Kropf; Axel Rominger; Clemens C Cyran
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

9.  Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy.

Authors:  Juan D Rojas; Fanglue Lin; Yun-Chen Chiang; Anna Chytil; Diana C Chong; Victoria L Bautch; W Kimryn Rathmell; Paul A Dayton
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

10.  Quantitative Three-Dimensional Dynamic Contrast-Enhanced Ultrasound Imaging: First-In-Human Pilot Study in Patients with Liver Metastases.

Authors:  Ahmed El Kaffas; Rosa Maria Silveira Sigrist; George Fisher; Sunitha Bachawal; Joy Liau; Huaijun Wang; Alexander Karanany; Isabelle Durot; Jarrett Rosenberg; Dimitre Hristov; Jürgen K Willmann
Journal:  Theranostics       Date:  2017-08-23       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.